To determine whether these dual activities of ganetespib on JAK2/STAT signaling and cell cycle progression observed in vitro translate into antitumor efficacy in vivo, we established an orthotopic leukemia model using HEL92.1.7 cells. The gene discussed is JAK2; the disease is leukemia.